Tonix: Maintaining Buy Rating With Potential Tonmya Expansion Indications

Core Insights - The article discusses Tonix Pharmaceuticals Holding Corp. (TNXP) and its potential to develop the first new fibromyalgia drug in 15 years [2]. Company Overview - Tonix Pharmaceuticals is highlighted for its focus on the biotech sector, particularly in developing treatments for fibromyalgia [2]. - The company is part of a broader analysis service that provides insights into various pharmaceutical companies [1]. Analyst Background - The analysis is conducted by Terry Chrisomalis, who has extensive experience in the biotech sector and offers a library of over 600 articles related to biotech investing [2]. - The service includes a model portfolio of small and mid-cap stocks, live chat, and various analysis reports to assist healthcare investors [2].